Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Novo Nordisk ( (NVO) ) has issued an announcement.
On 15 June 2026, Novo Nordisk provided an update on its ongoing share repurchase programme launched on 4 February 2026, which aims to buy back up to DKK 15 billion of B shares over 12 months. The buybacks are executed under EU Safe Harbour rules, signalling continued capital-return commitments and confidence in the company’s long-term prospects.
Under the specific programme initiated on 6 May 2026, the company plans to repurchase up to DKK 11.2 billion of B shares through 1 February 2027 and, between 8 and 12 June 2026, acquired 1,125,000 B shares, bringing accumulated purchases under this tranche to 5,125,000 shares worth DKK 1.47 billion. As of 12 June 2026, Novo Nordisk held 37,069,480 B shares as treasury stock, equal to 0.8% of its share capital, and had repurchased 19,884,179 B shares for DKK 5.27 billion since 4 February, underscoring ongoing balance-sheet deployment that may support earnings per share and shareholder returns.
The most recent analyst rating on (NVO) stock is a Hold
with a $45.00 price target.
To see the full list of analyst forecasts on Novo Nordisk stock,
see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.
The score is driven primarily by strong underlying profitability and multi-year revenue growth, supported by an attractive valuation (low P/E and solid dividend). The main offsets are higher leverage and weaker recent free-cash-flow conversion, alongside neutral-to-weak technical positioning relative to key moving averages and KPI-indicated concentration/region volatility that can pressure near-term consistency.
To see Spark’s full report on NVO stock,
click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, focused on defeating serious chronic diseases with a heritage in diabetes care. The group pioneers scientific breakthroughs, expands access to its medicines and prevention efforts, and markets its therapies in about 170 countries, with B shares listed on Nasdaq Copenhagen and ADRs on the New York Stock Exchange.
Average Trading Volume: 16,138,567
Technical Sentiment Signal: Sell
Current Market Cap: $198.1B
For an in-depth examination of NVO stock, go to TipRanks’ Overview page.